JP2011525535A

JP2011525535A - ＰＩ３Ｋ／ｍＴＯＲ阻害剤

ＰＩ３Ｋ／ｍＴＯＲ阻害剤 Download PDF

Info

Publication number: JP2011525535A
Authority: JP; Japan
Prior art keywords: alkyl; hetero; aryl; compound; halo
Prior art date: 2008-06-24
Legal status : Withdrawn

Application number

JP2011516533A

Other languages

English (en)

Japanese (ja)

Other versions

JP2011525535A5 (OSRAM

Inventor

シャンチャンゴン

ボハンジン

雅朗広瀬

フェンゾウ

キンドン

Current Assignee

Takeda Pharmaceutical Co Ltd

Original Assignee

Takeda Pharmaceutical Co Ltd

Priority date

2008-06-24

Filing date

2009-06-23

Publication date

2011-09-22

2009-06-23 Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd

2011-09-22 Publication of JP2011525535A publication Critical patent/JP2011525535A/ja

2012-08-09 Publication of JP2011525535A5 publication Critical patent/JP2011525535A5/ja

Status Withdrawn legal-status Critical Current

Links

239000012823 PI3K/mTOR inhibitor Substances 0.000 title description 9
150000001875 compounds Chemical class 0.000 claims abstract description 399
238000000034 method Methods 0.000 claims abstract description 113
108091007960 PI3Ks Proteins 0.000 claims abstract description 112
102000013530 TOR Serine-Threonine Kinases Human genes 0.000 claims abstract description 28
108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims abstract description 28
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 14
125000005842 heteroatom Chemical group 0.000 claims description 889
125000000217 alkyl group Chemical group 0.000 claims description 859
125000003118 aryl group Chemical group 0.000 claims description 482
-1 cyano, thio, oxy, hydroxy, carbonyloxy Chemical group 0.000 claims description 318
150000001334 alicyclic compounds Chemical class 0.000 claims description 262
125000005843 halogen group Chemical group 0.000 claims description 219
229910052739 hydrogen Inorganic materials 0.000 claims description 196
239000001257 hydrogen Substances 0.000 claims description 196
125000000753 cycloalkyl group Chemical group 0.000 claims description 181
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 178
150000002431 hydrogen Chemical class 0.000 claims description 152
125000004104 aryloxy group Chemical group 0.000 claims description 142
125000001424 substituent group Chemical group 0.000 claims description 126
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 118
108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 claims description 110
125000003342 alkenyl group Chemical group 0.000 claims description 101
125000000304 alkynyl group Chemical group 0.000 claims description 101
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 99
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 99
201000010099 disease Diseases 0.000 claims description 98
125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 85
125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 claims description 82
125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims description 81
125000003282 alkyl amino group Chemical group 0.000 claims description 71
125000000027 (C1-C10) alkoxy group Chemical group 0.000 claims description 70
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 67
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 66
125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 65
125000002723 alicyclic group Chemical group 0.000 claims description 65
125000005188 oxoalkyl group Chemical group 0.000 claims description 59
125000004093 cyano group Chemical group *C#N 0.000 claims description 58
125000006413 ring segment Chemical group 0.000 claims description 58
206010028980 Neoplasm Diseases 0.000 claims description 54
125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 46
238000001727 in vivo Methods 0.000 claims description 45
239000000203 mixture Substances 0.000 claims description 42
230000000694 effects Effects 0.000 claims description 38
125000004043 oxo group Chemical group O=* 0.000 claims description 37
125000001072 heteroaryl group Chemical group 0.000 claims description 36
201000011510 cancer Diseases 0.000 claims description 34
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 33
230000002401 inhibitory effect Effects 0.000 claims description 33
125000000714 pyrimidinyl group Chemical group 0.000 claims description 33
125000005708 carbonyloxy group Chemical group [*:2]OC([*:1])=O 0.000 claims description 31
230000007170 pathology Effects 0.000 claims description 31
125000004076 pyridyl group Chemical group 0.000 claims description 27
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 25
229910052799 carbon Inorganic materials 0.000 claims description 25
125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims description 24
208000024891 symptom Diseases 0.000 claims description 23
229910052757 nitrogen Inorganic materials 0.000 claims description 22
125000001153 fluoro group Chemical group F* 0.000 claims description 20
125000003373 pyrazinyl group Chemical group 0.000 claims description 20
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 20
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 19
229910052760 oxygen Inorganic materials 0.000 claims description 17
229920006395 saturated elastomer Polymers 0.000 claims description 17
125000003545 alkoxy group Chemical group 0.000 claims description 16
239000003814 drug Substances 0.000 claims description 16
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 16
238000011282 treatment Methods 0.000 claims description 16
125000000592 heterocycloalkyl group Chemical group 0.000 claims description 15
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 15
125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 13
150000003839 salts Chemical class 0.000 claims description 12
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 11
230000008569 process Effects 0.000 claims description 11
125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 claims description 11
125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 9
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
125000003277 amino group Chemical group 0.000 claims description 9
208000032839 leukemia Diseases 0.000 claims description 9
238000004519 manufacturing process Methods 0.000 claims description 9
229910052717 sulfur Inorganic materials 0.000 claims description 9
125000004845 (C1-C6) alkylsulfonylamino group Chemical group 0.000 claims description 8
239000005022 packaging material Substances 0.000 claims description 8
206010025323 Lymphomas Diseases 0.000 claims description 7
125000001309 chloro group Chemical group Cl* 0.000 claims description 7
208000037976 chronic inflammation Diseases 0.000 claims description 7
239000002552 dosage form Substances 0.000 claims description 7
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims description 6
208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 6
208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 6
208000034578 Multiple myelomas Diseases 0.000 claims description 6
206010035226 Plasma cell myeloma Diseases 0.000 claims description 6
206010060862 Prostate cancer Diseases 0.000 claims description 6
208000000236 Prostatic Neoplasms Diseases 0.000 claims description 6
206010041067 Small cell lung cancer Diseases 0.000 claims description 6
125000004122 cyclic group Chemical group 0.000 claims description 6
125000001841 imino group Chemical group [H]N=* 0.000 claims description 6
208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 6
208000000587 small cell lung carcinoma Diseases 0.000 claims description 6
238000003860 storage Methods 0.000 claims description 6
208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 6
125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 5
206010060891 General symptom Diseases 0.000 claims description 5
208000032612 Glial tumor Diseases 0.000 claims description 5
206010018338 Glioma Diseases 0.000 claims description 5
208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 5
125000004391 aryl sulfonyl group Chemical group 0.000 claims description 5
210000000481 breast Anatomy 0.000 claims description 5
208000014829 head and neck neoplasm Diseases 0.000 claims description 5
210000003734 kidney Anatomy 0.000 claims description 5
210000004072 lung Anatomy 0.000 claims description 5
210000001672 ovary Anatomy 0.000 claims description 5
125000004750 (C1-C6) alkylaminosulfonyl group Chemical group 0.000 claims description 4
125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims description 4
208000026310 Breast neoplasm Diseases 0.000 claims description 4
125000005141 aryl amino sulfonyl group Chemical group 0.000 claims description 4
210000000013 bile duct Anatomy 0.000 claims description 4
210000000988 bone and bone Anatomy 0.000 claims description 4
210000003169 central nervous system Anatomy 0.000 claims description 4
210000003679 cervix uteri Anatomy 0.000 claims description 4
230000006020 chronic inflammation Effects 0.000 claims description 4
230000002496 gastric effect Effects 0.000 claims description 4
210000003128 head Anatomy 0.000 claims description 4
125000004404 heteroalkyl group Chemical group 0.000 claims description 4
239000012669 liquid formulation Substances 0.000 claims description 4
210000004185 liver Anatomy 0.000 claims description 4
NWPPMBIAADIGOJ-UHFFFAOYSA-N n-[5-[4-(2-cyanopropan-2-yl)phenyl]-[1,3]thiazolo[5,4-b]pyridin-2-yl]acetamide Chemical compound N1=C2SC(NC(=O)C)=NC2=CC=C1C1=CC=C(C(C)(C)C#N)C=C1 NWPPMBIAADIGOJ-UHFFFAOYSA-N 0.000 claims description 4
210000003739 neck Anatomy 0.000 claims description 4
210000000496 pancreas Anatomy 0.000 claims description 4
210000003491 skin Anatomy 0.000 claims description 4
238000006467 substitution reaction Methods 0.000 claims description 4
210000001550 testis Anatomy 0.000 claims description 4
210000001685 thyroid gland Anatomy 0.000 claims description 4
210000001519 tissue Anatomy 0.000 claims description 4
210000003932 urinary bladder Anatomy 0.000 claims description 4
210000004291 uterus Anatomy 0.000 claims description 4
206010006187 Breast cancer Diseases 0.000 claims description 3
201000009030 Carcinoma Diseases 0.000 claims description 3
206010009944 Colon cancer Diseases 0.000 claims description 3
206010061218 Inflammation Diseases 0.000 claims description 3
208000022559 Inflammatory bowel disease Diseases 0.000 claims description 3
206010033128 Ovarian cancer Diseases 0.000 claims description 3
206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
239000004480 active ingredient Substances 0.000 claims description 3
229910052794 bromium Inorganic materials 0.000 claims description 3
208000037893 chronic inflammatory disorder Diseases 0.000 claims description 3
150000001923 cyclic compounds Chemical class 0.000 claims description 3
125000002541 furyl group Chemical group 0.000 claims description 3
208000005017 glioblastoma Diseases 0.000 claims description 3
125000002883 imidazolyl group Chemical group 0.000 claims description 3
230000004054 inflammatory process Effects 0.000 claims description 3
125000001786 isothiazolyl group Chemical group 0.000 claims description 3
125000000842 isoxazolyl group Chemical group 0.000 claims description 3
239000002502 liposome Substances 0.000 claims description 3
HZGRRWLRMQEMEZ-UHFFFAOYSA-N n-[5-(1h-indazol-5-yl)-[1,3]thiazolo[5,4-b]pyridin-2-yl]acetamide Chemical compound C1=C2NN=CC2=CC(C2=CC=C3N=C(SC3=N2)NC(=O)C)=C1 HZGRRWLRMQEMEZ-UHFFFAOYSA-N 0.000 claims description 3
VAIYPNDMNWYSLG-UHFFFAOYSA-N n-[5-(1h-indol-5-yl)-[1,3]thiazolo[5,4-b]pyridin-2-yl]acetamide Chemical compound C1=C2NC=CC2=CC(C2=CC=C3N=C(SC3=N2)NC(=O)C)=C1 VAIYPNDMNWYSLG-UHFFFAOYSA-N 0.000 claims description 3
BCQNLVNUDIISOD-UHFFFAOYSA-N n-[5-(1h-pyrrolo[3,2-b]pyridin-6-yl)-[1,3]thiazolo[5,4-b]pyridin-2-yl]acetamide Chemical compound N1=C2C=CNC2=CC(C2=CC=C3N=C(SC3=N2)NC(=O)C)=C1 BCQNLVNUDIISOD-UHFFFAOYSA-N 0.000 claims description 3
YYNGLPPFNWLREN-UHFFFAOYSA-N n-[5-(2-acetamido-[1,3]thiazolo[5,4-b]pyridin-5-yl)pyridin-2-yl]acetamide Chemical compound N1=C2SC(NC(=O)C)=NC2=CC=C1C1=CC=C(NC(C)=O)N=C1 YYNGLPPFNWLREN-UHFFFAOYSA-N 0.000 claims description 3
GOYHGFBTKDADTO-UHFFFAOYSA-N n-[6-(4-aminophenyl)-1,3-benzothiazol-2-yl]acetamide Chemical compound C1=C2SC(NC(=O)C)=NC2=CC=C1C1=CC=C(N)C=C1 GOYHGFBTKDADTO-UHFFFAOYSA-N 0.000 claims description 3
125000001715 oxadiazolyl group Chemical group 0.000 claims description 3
125000002971 oxazolyl group Chemical group 0.000 claims description 3
125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 3
125000003226 pyrazolyl group Chemical group 0.000 claims description 3
206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
125000000335 thiazolyl group Chemical group 0.000 claims description 3
125000001425 triazolyl group Chemical group 0.000 claims description 3
210000003905 vulva Anatomy 0.000 claims description 3
CASWGGBDRIPWFE-LLVKDONJSA-N (2r)-n-[5-[6-chloro-5-(methanesulfonamido)pyridin-3-yl]-[1,3]thiazolo[5,4-b]pyridin-2-yl]-2,3-dihydroxypropanamide Chemical compound N1=C(Cl)C(NS(=O)(=O)C)=CC(C=2N=C3SC(NC(=O)[C@H](O)CO)=NC3=CC=2)=C1 CASWGGBDRIPWFE-LLVKDONJSA-N 0.000 claims description 2
CASWGGBDRIPWFE-NSHDSACASA-N (2s)-n-[5-[6-chloro-5-(methanesulfonamido)pyridin-3-yl]-[1,3]thiazolo[5,4-b]pyridin-2-yl]-2,3-dihydroxypropanamide Chemical compound N1=C(Cl)C(NS(=O)(=O)C)=CC(C=2N=C3SC(NC(=O)[C@@H](O)CO)=NC3=CC=2)=C1 CASWGGBDRIPWFE-NSHDSACASA-N 0.000 claims description 2
HFUOWPYMLABQJR-SECBINFHSA-N (3r)-n-[5-[6-chloro-5-(methanesulfonamido)pyridin-3-yl]-[1,3]thiazolo[5,4-b]pyridin-2-yl]-3,4-dihydroxybutanamide Chemical compound N1=C(Cl)C(NS(=O)(=O)C)=CC(C=2N=C3SC(NC(=O)C[C@@H](O)CO)=NC3=CC=2)=C1 HFUOWPYMLABQJR-SECBINFHSA-N 0.000 claims description 2
HFUOWPYMLABQJR-VIFPVBQESA-N (3s)-n-[5-[6-chloro-5-(methanesulfonamido)pyridin-3-yl]-[1,3]thiazolo[5,4-b]pyridin-2-yl]-3,4-dihydroxybutanamide Chemical compound N1=C(Cl)C(NS(=O)(=O)C)=CC(C=2N=C3SC(NC(=O)C[C@H](O)CO)=NC3=CC=2)=C1 HFUOWPYMLABQJR-VIFPVBQESA-N 0.000 claims description 2
ZIJOJSRASSFKTL-UHFFFAOYSA-N 3-(2-acetamido-1,3-benzothiazol-6-yl)-n-methylbenzamide Chemical compound CNC(=O)C1=CC=CC(C=2C=C3SC(NC(C)=O)=NC3=CC=2)=C1 ZIJOJSRASSFKTL-UHFFFAOYSA-N 0.000 claims description 2
VFBKFNBDAJTNOI-UHFFFAOYSA-N 3-(2-acetamido-[1,3]thiazolo[5,4-b]pyridin-5-yl)-n-methoxybenzamide Chemical compound CONC(=O)C1=CC=CC(C=2N=C3SC(NC(C)=O)=NC3=CC=2)=C1 VFBKFNBDAJTNOI-UHFFFAOYSA-N 0.000 claims description 2
XSWDBJCYUKIAFA-UHFFFAOYSA-N 4-(2-acetamido-[1,3]thiazolo[5,4-b]pyridin-5-yl)-n-cyclopropylbenzamide Chemical compound N1=C2SC(NC(=O)C)=NC2=CC=C1C(C=C1)=CC=C1C(=O)NC1CC1 XSWDBJCYUKIAFA-UHFFFAOYSA-N 0.000 claims description 2
YTYBVOIGPDDBMK-UHFFFAOYSA-N 4-(2-acetamido-[1,3]thiazolo[5,4-b]pyridin-5-yl)-n-methoxybenzamide Chemical compound C1=CC(C(=O)NOC)=CC=C1C1=CC=C(N=C(NC(C)=O)S2)C2=N1 YTYBVOIGPDDBMK-UHFFFAOYSA-N 0.000 claims description 2
LZNOTFGSIYBDNI-UHFFFAOYSA-N 4-(2-acetamido-[1,3]thiazolo[5,4-b]pyridin-5-yl)-n-methylbenzamide Chemical compound C1=CC(C(=O)NC)=CC=C1C1=CC=C(N=C(NC(C)=O)S2)C2=N1 LZNOTFGSIYBDNI-UHFFFAOYSA-N 0.000 claims description 2
ILIQYEYPKRXSHV-UHFFFAOYSA-N 5-(2-acetamido-1,3-benzothiazol-6-yl)-1h-indole-3-carboxamide Chemical compound C1=C2NC=C(C(N)=O)C2=CC(C2=CC=C3N=C(SC3=C2)NC(=O)C)=C1 ILIQYEYPKRXSHV-UHFFFAOYSA-N 0.000 claims description 2
QGHSIDJGALMPKO-UHFFFAOYSA-N 5-(2-acetamido-[1,3]thiazolo[5,4-b]pyridin-5-yl)-n-methylpyridine-2-carboxamide Chemical compound C1=NC(C(=O)NC)=CC=C1C1=CC=C(N=C(NC(C)=O)S2)C2=N1 QGHSIDJGALMPKO-UHFFFAOYSA-N 0.000 claims description 2
XTHKRYHULUJQHN-UHFFFAOYSA-N 6-bromopyridin-3-amine Chemical compound NC1=CC=C(Br)N=C1 XTHKRYHULUJQHN-UHFFFAOYSA-N 0.000 claims description 2
208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
206010003571 Astrocytoma Diseases 0.000 claims description 2
206010005003 Bladder cancer Diseases 0.000 claims description 2
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
208000024172 Cardiovascular disease Diseases 0.000 claims description 2
208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 2
206010020751 Hypersensitivity Diseases 0.000 claims description 2
208000007766 Kaposi sarcoma Diseases 0.000 claims description 2
208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
206010027406 Mesothelioma Diseases 0.000 claims description 2
206010027476 Metastases Diseases 0.000 claims description 2
201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 2
208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
201000004681 Psoriasis Diseases 0.000 claims description 2
206010038389 Renal cancer Diseases 0.000 claims description 2
208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
208000008385 Urogenital Neoplasms Diseases 0.000 claims description 2
208000012544 Viral Skin disease Diseases 0.000 claims description 2
208000036142 Viral infection Diseases 0.000 claims description 2
208000026935 allergic disease Diseases 0.000 claims description 2
230000007815 allergy Effects 0.000 claims description 2
230000033115 angiogenesis Effects 0.000 claims description 2
208000006673 asthma Diseases 0.000 claims description 2
125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 2
125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 2
125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 2
125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
238000009472 formulation Methods 0.000 claims description 2
201000010536 head and neck cancer Diseases 0.000 claims description 2
201000005787 hematologic cancer Diseases 0.000 claims description 2
208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 2
208000026278 immune system disease Diseases 0.000 claims description 2
125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 2
125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 claims description 2
238000001361 intraarterial administration Methods 0.000 claims description 2
238000007918 intramuscular administration Methods 0.000 claims description 2
238000007912 intraperitoneal administration Methods 0.000 claims description 2
238000007913 intrathecal administration Methods 0.000 claims description 2
238000001990 intravenous administration Methods 0.000 claims description 2
125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims description 2
201000010982 kidney cancer Diseases 0.000 claims description 2
201000001441 melanoma Diseases 0.000 claims description 2
230000009401 metastasis Effects 0.000 claims description 2
ZMYCJRNDIOYCEH-UHFFFAOYSA-N n-(5-imidazo[1,2-a]pyridin-6-yl-[1,3]thiazolo[5,4-b]pyridin-2-yl)acetamide Chemical compound C1=CC2=NC=CN2C=C1C1=CC=C2N=C(NC(=O)C)SC2=N1 ZMYCJRNDIOYCEH-UHFFFAOYSA-N 0.000 claims description 2
XLEPKBITASKFNA-UHFFFAOYSA-N n-(5-pyridin-4-yl-[1,3]thiazolo[5,4-b]pyridin-2-yl)acetamide Chemical compound N1=C2SC(NC(=O)C)=NC2=CC=C1C1=CC=NC=C1 XLEPKBITASKFNA-UHFFFAOYSA-N 0.000 claims description 2
QRKJGBJCNLLUER-UHFFFAOYSA-N n-(6-phenyl-1,3-benzothiazol-2-yl)acetamide Chemical compound C1=C2SC(NC(=O)C)=NC2=CC=C1C1=CC=CC=C1 QRKJGBJCNLLUER-UHFFFAOYSA-N 0.000 claims description 2
IRENWYOEYVTIRD-UHFFFAOYSA-N n-(6-pyridin-3-yl-1,3-benzothiazol-2-yl)acetamide Chemical compound C1=C2SC(NC(=O)C)=NC2=CC=C1C1=CC=CN=C1 IRENWYOEYVTIRD-UHFFFAOYSA-N 0.000 claims description 2
BZGXHWVLGYQPGJ-UHFFFAOYSA-N n-[3-(2-acetamido-1,3-benzothiazol-6-yl)phenyl]acetamide Chemical compound C1=C2SC(NC(=O)C)=NC2=CC=C1C1=CC=CC(NC(C)=O)=C1 BZGXHWVLGYQPGJ-UHFFFAOYSA-N 0.000 claims description 2
VLBIDLXFCOFYIC-UHFFFAOYSA-N n-[4-(2-acetamido-1,3-benzothiazol-6-yl)phenyl]acetamide Chemical compound C1=C2SC(NC(=O)C)=NC2=CC=C1C1=CC=C(NC(C)=O)C=C1 VLBIDLXFCOFYIC-UHFFFAOYSA-N 0.000 claims description 2
AXAAKZSLIROZMB-UHFFFAOYSA-N n-[4-(2-acetamido-[1,3]thiazolo[5,4-b]pyridin-5-yl)phenyl]acetamide Chemical compound N1=C2SC(NC(=O)C)=NC2=CC=C1C1=CC=C(NC(C)=O)C=C1 AXAAKZSLIROZMB-UHFFFAOYSA-N 0.000 claims description 2
DDKVONMINQTCQU-UHFFFAOYSA-N n-[5-(1,3-dimethyl-2-oxoimidazo[4,5-b]pyridin-6-yl)-[1,3]thiazolo[5,4-b]pyridin-2-yl]acetamide Chemical compound N1=C2N(C)C(=O)N(C)C2=CC(C2=CC=C3N=C(SC3=N2)NC(=O)C)=C1 DDKVONMINQTCQU-UHFFFAOYSA-N 0.000 claims description 2
MWWXCDNZLWDQDP-UHFFFAOYSA-N n-[5-(1-methylsulfonyl-2h-pyrrolo[3,4-b]pyridin-6-yl)-[1,3]thiazolo[5,4-b]pyridin-2-yl]acetamide Chemical compound C1=C2C=CCN(S(C)(=O)=O)C2=CN1C1=CC=C2N=C(NC(=O)C)SC2=N1 MWWXCDNZLWDQDP-UHFFFAOYSA-N 0.000 claims description 2
CGVPAAPAOPGGBA-UHFFFAOYSA-N n-[5-(1-methylsulfonylpyrrolo[3,4-b]pyridin-3-yl)-[1,3]thiazolo[5,4-b]pyridin-2-yl]acetamide Chemical compound CS(=O)(=O)N1C2=CN=CC2=CC(C2=CC=C3N=C(SC3=N2)NC(=O)C)=C1 CGVPAAPAOPGGBA-UHFFFAOYSA-N 0.000 claims description 2
SETPDRDLPUJVJN-UHFFFAOYSA-N n-[5-(1h-imidazo[4,5-b]pyridin-6-yl)-[1,3]thiazolo[5,4-b]pyridin-2-yl]acetamide Chemical compound N1=C2NC=NC2=CC(C2=CC=C3N=C(SC3=N2)NC(=O)C)=C1 SETPDRDLPUJVJN-UHFFFAOYSA-N 0.000 claims description 2
INJDMOJUKFSRQR-UHFFFAOYSA-N n-[5-(1h-indazol-4-yl)-[1,3]thiazolo[5,4-b]pyridin-2-yl]acetamide Chemical compound N1=C2SC(NC(=O)C)=NC2=CC=C1C1=CC=CC2=C1C=NN2 INJDMOJUKFSRQR-UHFFFAOYSA-N 0.000 claims description 2
IDVIRXWXYIPVSK-UHFFFAOYSA-N n-[5-(1h-pyrazolo[3,4-b]pyridin-5-yl)-[1,3]thiazolo[5,4-b]pyridin-2-yl]acetamide Chemical compound N1=C2NN=CC2=CC(C2=CC=C3N=C(SC3=N2)NC(=O)C)=C1 IDVIRXWXYIPVSK-UHFFFAOYSA-N 0.000 claims description 2
NKXBHCJZIWMXKN-UHFFFAOYSA-N n-[5-(1h-pyrazolo[4,3-b]pyridin-6-yl)-[1,3]thiazolo[5,4-b]pyridin-2-yl]acetamide Chemical compound N1=C2C=NNC2=CC(C2=CC=C3N=C(SC3=N2)NC(=O)C)=C1 NKXBHCJZIWMXKN-UHFFFAOYSA-N 0.000 claims description 2
CTPOPACZQCQCHH-UHFFFAOYSA-N n-[5-(1h-pyrrolo[2,3-b]pyridin-5-yl)-[1,3]thiazolo[5,4-b]pyridin-2-yl]acetamide Chemical compound N1=C2NC=CC2=CC(C2=CC=C3N=C(SC3=N2)NC(=O)C)=C1 CTPOPACZQCQCHH-UHFFFAOYSA-N 0.000 claims description 2
PDZTVXKZHHTLJQ-UHFFFAOYSA-N n-[5-(2-aminophenyl)-[1,3]thiazolo[5,4-b]pyridin-2-yl]acetamide Chemical compound N1=C2SC(NC(=O)C)=NC2=CC=C1C1=CC=CC=C1N PDZTVXKZHHTLJQ-UHFFFAOYSA-N 0.000 claims description 2
VLNLLBHVYOPRLT-UHFFFAOYSA-N n-[5-(2-oxo-1,3-dihydroindol-5-yl)-[1,3]thiazolo[5,4-b]pyridin-2-yl]acetamide Chemical compound C1=C2NC(=O)CC2=CC(C2=CC=C3N=C(SC3=N2)NC(=O)C)=C1 VLNLLBHVYOPRLT-UHFFFAOYSA-N 0.000 claims description 2
SKXRMAWMLLBRQZ-UHFFFAOYSA-N n-[5-(4-methylsulfonylphenyl)-[1,3]thiazolo[5,4-b]pyridin-2-yl]acetamide Chemical compound N1=C2SC(NC(=O)C)=NC2=CC=C1C1=CC=C(S(C)(=O)=O)C=C1 SKXRMAWMLLBRQZ-UHFFFAOYSA-N 0.000 claims description 2
OHEURRCKFZFXCN-UHFFFAOYSA-N n-[5-(5-amino-6-chloropyridin-3-yl)-[1,3]thiazolo[5,4-d]pyrimidin-2-yl]acetamide Chemical compound N1=C2SC(NC(=O)C)=NC2=CN=C1C1=CN=C(Cl)C(N)=C1 OHEURRCKFZFXCN-UHFFFAOYSA-N 0.000 claims description 2
PXQUDTYFWUYPMT-UHFFFAOYSA-N n-[5-(5-oxo-6,7-dihydropyrrolo[3,4-b]pyridin-3-yl)-[1,3]thiazolo[5,4-b]pyridin-2-yl]acetamide Chemical compound N1=C2CNC(=O)C2=CC(C2=CC=C3N=C(SC3=N2)NC(=O)C)=C1 PXQUDTYFWUYPMT-UHFFFAOYSA-N 0.000 claims description 2
FQVXJCFYTSWIMB-UHFFFAOYSA-N n-[5-(6-aminopyridin-3-yl)-[1,3]thiazolo[5,4-d]pyrimidin-2-yl]acetamide Chemical compound N1=C2SC(NC(=O)C)=NC2=CN=C1C1=CC=C(N)N=C1 FQVXJCFYTSWIMB-UHFFFAOYSA-N 0.000 claims description 2
HEBLCEOQSXKBQJ-UHFFFAOYSA-N n-[5-(6-cyanopyridin-3-yl)-[1,3]thiazolo[5,4-b]pyridin-2-yl]acetamide Chemical compound N1=C2SC(NC(=O)C)=NC2=CC=C1C1=CC=C(C#N)N=C1 HEBLCEOQSXKBQJ-UHFFFAOYSA-N 0.000 claims description 2
WIESYCKLQAZXHL-UHFFFAOYSA-N n-[5-(7-oxo-5,6-dihydropyrrolo[3,4-b]pyridin-3-yl)-[1,3]thiazolo[5,4-b]pyridin-2-yl]acetamide Chemical compound N1=C2C(=O)NCC2=CC(C2=CC=C3N=C(SC3=N2)NC(=O)C)=C1 WIESYCKLQAZXHL-UHFFFAOYSA-N 0.000 claims description 2
MXVUHFNCWPTIRX-UHFFFAOYSA-N n-[5-([1,3]oxazolo[4,5-b]pyridin-6-yl)-[1,3]thiazolo[5,4-b]pyridin-2-yl]acetamide Chemical compound N1=C2N=COC2=CC(C2=CC=C3N=C(SC3=N2)NC(=O)C)=C1 MXVUHFNCWPTIRX-UHFFFAOYSA-N 0.000 claims description 2
XRVZSMFIMPVHLJ-UHFFFAOYSA-N n-[5-([1,3]oxazolo[5,4-b]pyridin-6-yl)-[1,3]thiazolo[5,4-b]pyridin-2-yl]acetamide Chemical compound N1=C2OC=NC2=CC(C2=CC=C3N=C(SC3=N2)NC(=O)C)=C1 XRVZSMFIMPVHLJ-UHFFFAOYSA-N 0.000 claims description 2
WWJNYVGZISJMIP-UHFFFAOYSA-N n-[5-[4-(1h-1,2,4-triazol-5-yl)phenyl]-[1,3]thiazolo[5,4-b]pyridin-2-yl]acetamide Chemical compound N1=C2SC(NC(=O)C)=NC2=CC=C1C(C=C1)=CC=C1C1=NN=CN1 WWJNYVGZISJMIP-UHFFFAOYSA-N 0.000 claims description 2
REQAWDMBIJHYIW-UHFFFAOYSA-N n-[5-[4-(methanesulfonamido)phenyl]-[1,3]thiazolo[5,4-b]pyridin-2-yl]acetamide Chemical compound N1=C2SC(NC(=O)C)=NC2=CC=C1C1=CC=C(NS(C)(=O)=O)C=C1 REQAWDMBIJHYIW-UHFFFAOYSA-N 0.000 claims description 2
UCURIPUEWNUHJA-UHFFFAOYSA-N n-[5-[4-(methylsulfamoyl)phenyl]-[1,3]thiazolo[5,4-b]pyridin-2-yl]acetamide Chemical compound C1=CC(S(=O)(=O)NC)=CC=C1C1=CC=C(N=C(NC(C)=O)S2)C2=N1 UCURIPUEWNUHJA-UHFFFAOYSA-N 0.000 claims description 2
APJDNYVSNCTPEF-UHFFFAOYSA-N n-[5-[5-(benzenesulfonamido)-6-chloropyridin-3-yl]-[1,3]thiazolo[5,4-b]pyridin-2-yl]acetamide Chemical compound N1=C2SC(NC(=O)C)=NC2=CC=C1C(C=1)=CN=C(Cl)C=1NS(=O)(=O)C1=CC=CC=C1 APJDNYVSNCTPEF-UHFFFAOYSA-N 0.000 claims description 2
GEWZFIJSNQDMAD-UHFFFAOYSA-N n-[5-[5-(benzenesulfonamido)-6-chloropyridin-3-yl]-[1,3]thiazolo[5,4-d]pyrimidin-2-yl]acetamide Chemical compound N1=C2SC(NC(=O)C)=NC2=CN=C1C(C=1)=CN=C(Cl)C=1NS(=O)(=O)C1=CC=CC=C1 GEWZFIJSNQDMAD-UHFFFAOYSA-N 0.000 claims description 2
UNTKVVYKIJQQEG-UHFFFAOYSA-N n-[5-[5-chloro-6-(methanesulfonamido)imidazo[1,5-a]pyridin-8-yl]-[1,3]thiazolo[5,4-b]pyridin-2-yl]acetamide Chemical compound CS(=O)(=O)NC1=C(Cl)N2C=NC=C2C(C2=CC=C3N=C(SC3=N2)NC(=O)C)=C1 UNTKVVYKIJQQEG-UHFFFAOYSA-N 0.000 claims description 2
QZYIUXSWZHBIST-UHFFFAOYSA-N n-[5-[6-amino-5-(trifluoromethyl)pyridin-3-yl]-[1,3]thiazolo[5,4-d]pyrimidin-2-yl]acetamide Chemical compound N1=C2SC(NC(=O)C)=NC2=CN=C1C1=CN=C(N)C(C(F)(F)F)=C1 QZYIUXSWZHBIST-UHFFFAOYSA-N 0.000 claims description 2
HSEXKLYCMBPHKS-UHFFFAOYSA-N n-[5-[6-chloro-5-(1,3-dihydroxypropan-2-ylsulfonylamino)pyridin-3-yl]-[1,3]thiazolo[5,4-b]pyridin-2-yl]acetamide Chemical compound N1=C2SC(NC(=O)C)=NC2=CC=C1C1=CN=C(Cl)C(NS(=O)(=O)C(CO)CO)=C1 HSEXKLYCMBPHKS-UHFFFAOYSA-N 0.000 claims description 2
IFPKDHALYZARAO-UHFFFAOYSA-N n-[5-[6-chloro-5-(2-hydroxyethylsulfonylamino)pyridin-3-yl]-[1,3]thiazolo[5,4-b]pyridin-2-yl]acetamide Chemical compound N1=C2SC(NC(=O)C)=NC2=CC=C1C1=CN=C(Cl)C(NS(=O)(=O)CCO)=C1 IFPKDHALYZARAO-UHFFFAOYSA-N 0.000 claims description 2
ZTMRIMJRQRVLPM-UHFFFAOYSA-N n-[5-[6-chloro-5-(3-hydroxypropylsulfonylamino)pyridin-3-yl]-[1,3]thiazolo[5,4-b]pyridin-2-yl]acetamide Chemical compound N1=C2SC(NC(=O)C)=NC2=CC=C1C1=CN=C(Cl)C(NS(=O)(=O)CCCO)=C1 ZTMRIMJRQRVLPM-UHFFFAOYSA-N 0.000 claims description 2
AOLCWVRLUBBGLM-UHFFFAOYSA-N n-[5-[6-chloro-5-(cyclopropylsulfonylamino)pyridin-3-yl]-[1,3]thiazolo[5,4-b]pyridin-2-yl]acetamide Chemical compound N1=C2SC(NC(=O)C)=NC2=CC=C1C(C=1)=CN=C(Cl)C=1NS(=O)(=O)C1CC1 AOLCWVRLUBBGLM-UHFFFAOYSA-N 0.000 claims description 2
AQUJYSLJWWYNMP-UHFFFAOYSA-N n-[5-[6-chloro-5-(ethylsulfonylamino)pyridin-3-yl]-[1,3]thiazolo[5,4-b]pyridin-2-yl]acetamide Chemical compound N1=C(Cl)C(NS(=O)(=O)CC)=CC(C=2N=C3SC(NC(C)=O)=NC3=CC=2)=C1 AQUJYSLJWWYNMP-UHFFFAOYSA-N 0.000 claims description 2
XQUQJEHZNPNINA-UHFFFAOYSA-N n-[5-[6-chloro-5-(methanesulfonamido)pyridin-3-yl]-[1,3]thiazolo[5,4-b]pyridin-2-yl]-1-methylpiperidine-4-carboxamide Chemical compound C1CN(C)CCC1C(=O)NC1=NC2=CC=C(C=3C=C(NS(C)(=O)=O)C(Cl)=NC=3)N=C2S1 XQUQJEHZNPNINA-UHFFFAOYSA-N 0.000 claims description 2
AZIYVXZYRUKWPT-UHFFFAOYSA-N n-[5-[6-chloro-5-(methanesulfonamido)pyridin-3-yl]-[1,3]thiazolo[5,4-b]pyridin-2-yl]-2-hydroxyacetamide Chemical compound N1=C(Cl)C(NS(=O)(=O)C)=CC(C=2N=C3SC(NC(=O)CO)=NC3=CC=2)=C1 AZIYVXZYRUKWPT-UHFFFAOYSA-N 0.000 claims description 2
QOALRXHQGUKLCU-UHFFFAOYSA-N n-[5-[6-chloro-5-(methanesulfonamido)pyridin-3-yl]-[1,3]thiazolo[5,4-b]pyridin-2-yl]-3-hydroxypropanamide Chemical compound N1=C(Cl)C(NS(=O)(=O)C)=CC(C=2N=C3SC(NC(=O)CCO)=NC3=CC=2)=C1 QOALRXHQGUKLCU-UHFFFAOYSA-N 0.000 claims description 2
CKIAZVZZEGJOHA-UHFFFAOYSA-N n-[5-[6-chloro-5-(methanesulfonamido)pyridin-3-yl]-[1,3]thiazolo[5,4-b]pyridin-2-yl]acetamide Chemical compound N1=C2SC(NC(=O)C)=NC2=CC=C1C1=CN=C(Cl)C(NS(C)(=O)=O)=C1 CKIAZVZZEGJOHA-UHFFFAOYSA-N 0.000 claims description 2
RIXYUTONIVIZET-UHFFFAOYSA-N n-[5-[6-chloro-5-(methanesulfonamido)pyridin-3-yl]-[1,3]thiazolo[5,4-b]pyridin-2-yl]cyclopropanecarboxamide Chemical compound N1=C(Cl)C(NS(=O)(=O)C)=CC(C=2N=C3SC(NC(=O)C4CC4)=NC3=CC=2)=C1 RIXYUTONIVIZET-UHFFFAOYSA-N 0.000 claims description 2
UJHUFHZZWGFKBL-UHFFFAOYSA-N n-[5-[6-chloro-5-(methanesulfonamido)pyridin-3-yl]-[1,3]thiazolo[5,4-b]pyridin-2-yl]propanamide Chemical compound N1=C2SC(NC(=O)CC)=NC2=CC=C1C1=CN=C(Cl)C(NS(C)(=O)=O)=C1 UJHUFHZZWGFKBL-UHFFFAOYSA-N 0.000 claims description 2
UWNLMWMXFKHKDP-UHFFFAOYSA-N n-[5-[6-chloro-5-(methanesulfonamido)pyridin-3-yl]-[1,3]thiazolo[5,4-d]pyrimidin-2-yl]acetamide Chemical compound N1=C2SC(NC(=O)C)=NC2=CN=C1C1=CN=C(Cl)C(NS(C)(=O)=O)=C1 UWNLMWMXFKHKDP-UHFFFAOYSA-N 0.000 claims description 2
FXWZIKZVRDOMEW-UHFFFAOYSA-N n-[5-[6-chloro-5-[(1-methylpiperidin-4-yl)methylsulfonylamino]pyridin-3-yl]-[1,3]thiazolo[5,4-b]pyridin-2-yl]acetamide Chemical compound C1CN(C)CCC1CS(=O)(=O)NC1=CC(C=2N=C3SC(NC(C)=O)=NC3=CC=2)=CN=C1Cl FXWZIKZVRDOMEW-UHFFFAOYSA-N 0.000 claims description 2
TXQCKHSWLREUAY-UHFFFAOYSA-N n-[5-[6-chloro-5-[(1-methylpiperidin-4-yl)sulfonylamino]pyridin-3-yl]-[1,3]thiazolo[5,4-b]pyridin-2-yl]acetamide Chemical compound C1CN(C)CCC1S(=O)(=O)NC1=CC(C=2N=C3SC(NC(C)=O)=NC3=CC=2)=CN=C1Cl TXQCKHSWLREUAY-UHFFFAOYSA-N 0.000 claims description 2
KXVUBWDAIASJMV-UHFFFAOYSA-N n-[5-[6-chloro-5-[2-(dimethylamino)ethylsulfonylamino]pyridin-3-yl]-[1,3]thiazolo[5,4-b]pyridin-2-yl]acetamide Chemical compound N1=C(Cl)C(NS(=O)(=O)CCN(C)C)=CC(C=2N=C3SC(NC(C)=O)=NC3=CC=2)=C1 KXVUBWDAIASJMV-UHFFFAOYSA-N 0.000 claims description 2
DJPUWGRJEHBKOY-UHFFFAOYSA-N n-[5-[6-chloro-5-[3-(4-methylpiperazin-1-yl)propylsulfonylamino]pyridin-3-yl]-[1,3]thiazolo[5,4-b]pyridin-2-yl]acetamide Chemical compound C1CN(C)CCN1CCCS(=O)(=O)NC1=CC(C=2N=C3SC(NC(C)=O)=NC3=CC=2)=CN=C1Cl DJPUWGRJEHBKOY-UHFFFAOYSA-N 0.000 claims description 2
ZYQNRGZJEXJIHR-UHFFFAOYSA-N n-[5-[6-chloro-5-[3-(dimethylamino)propylsulfonylamino]pyridin-3-yl]-[1,3]thiazolo[5,4-b]pyridin-2-yl]acetamide Chemical compound N1=C(Cl)C(NS(=O)(=O)CCCN(C)C)=CC(C=2N=C3SC(NC(C)=O)=NC3=CC=2)=C1 ZYQNRGZJEXJIHR-UHFFFAOYSA-N 0.000 claims description 2
NXRNQLHUUREKNB-UHFFFAOYSA-N n-[5-[6-chloro-5-[[3-hydroxy-2-(hydroxymethyl)propyl]sulfonylamino]pyridin-3-yl]-[1,3]thiazolo[5,4-b]pyridin-2-yl]acetamide Chemical compound N1=C2SC(NC(=O)C)=NC2=CC=C1C1=CN=C(Cl)C(NS(=O)(=O)CC(CO)CO)=C1 NXRNQLHUUREKNB-UHFFFAOYSA-N 0.000 claims description 2
WXZVDKNCMNUDMQ-UHFFFAOYSA-N n-[5-[7-(methanesulfonamido)-1,3-benzoxazol-5-yl]-[1,3]thiazolo[5,4-b]pyridin-2-yl]acetamide Chemical compound CS(=O)(=O)NC1=C2OC=NC2=CC(C2=CC=C3N=C(SC3=N2)NC(=O)C)=C1 WXZVDKNCMNUDMQ-UHFFFAOYSA-N 0.000 claims description 2
XPUOFMUZZXQSPF-UHFFFAOYSA-N n-[5-[7-(methanesulfonamido)-3h-benzimidazol-5-yl]-[1,3]thiazolo[5,4-b]pyridin-2-yl]acetamide Chemical compound CS(=O)(=O)NC1=C2NC=NC2=CC(C2=CC=C3N=C(SC3=N2)NC(=O)C)=C1 XPUOFMUZZXQSPF-UHFFFAOYSA-N 0.000 claims description 2
IUUOHIPTKAZYOV-UHFFFAOYSA-N n-[6-(1h-indol-4-yl)-1,3-benzothiazol-2-yl]acetamide Chemical compound C1=C2SC(NC(=O)C)=NC2=CC=C1C1=CC=CC2=C1C=CN2 IUUOHIPTKAZYOV-UHFFFAOYSA-N 0.000 claims description 2
TYWOTXMIHZAUJU-UHFFFAOYSA-N n-[6-(1h-indol-5-yl)-1,3-benzothiazol-2-yl]acetamide Chemical compound C1=C2NC=CC2=CC(C2=CC=C3N=C(SC3=C2)NC(=O)C)=C1 TYWOTXMIHZAUJU-UHFFFAOYSA-N 0.000 claims description 2
UKMLSLPXXWOSGK-UHFFFAOYSA-N n-[6-(2,5-dioxo-3,4-dihydro-1h-1,4-benzodiazepin-8-yl)-1,3-benzothiazol-2-yl]acetamide Chemical compound N1C(=O)CNC(=O)C=2C1=CC(C1=CC=C3N=C(SC3=C1)NC(=O)C)=CC=2 UKMLSLPXXWOSGK-UHFFFAOYSA-N 0.000 claims description 2
WNZYIFHPKOGBHV-UHFFFAOYSA-N n-[6-(3-cyano-1h-indol-5-yl)-1,3-benzothiazol-2-yl]acetamide Chemical compound C1=C2NC=C(C#N)C2=CC(C2=CC=C3N=C(SC3=C2)NC(=O)C)=C1 WNZYIFHPKOGBHV-UHFFFAOYSA-N 0.000 claims description 2
YOTVUEUTUOTRGB-UHFFFAOYSA-N n-[6-(3-formyl-1h-indol-5-yl)-1,3-benzothiazol-2-yl]acetamide Chemical compound C1=C2NC=C(C=O)C2=CC(C2=CC=C3N=C(SC3=C2)NC(=O)C)=C1 YOTVUEUTUOTRGB-UHFFFAOYSA-N 0.000 claims description 2
CKXVFSGKHZVJGM-UHFFFAOYSA-N n-[6-(5-aminopyrazin-2-yl)-1,3-benzothiazol-2-yl]acetamide Chemical compound C1=C2SC(NC(=O)C)=NC2=CC=C1C1=CN=C(N)C=N1 CKXVFSGKHZVJGM-UHFFFAOYSA-N 0.000 claims description 2
ZZWRIYQCDZEVJW-UHFFFAOYSA-N n-[6-[4-amino-2-(trifluoromethyl)phenyl]-1,3-benzothiazol-2-yl]acetamide Chemical compound C1=C2SC(NC(=O)C)=NC2=CC=C1C1=CC=C(N)C=C1C(F)(F)F ZZWRIYQCDZEVJW-UHFFFAOYSA-N 0.000 claims description 2
YBKJDNVXZBTIRO-UHFFFAOYSA-N n-[6-[5-(benzenesulfonamido)-6-chloropyridin-3-yl]-1,3-benzothiazol-2-yl]acetamide Chemical compound C1=C2SC(NC(=O)C)=NC2=CC=C1C(C=1)=CN=C(Cl)C=1NS(=O)(=O)C1=CC=CC=C1 YBKJDNVXZBTIRO-UHFFFAOYSA-N 0.000 claims description 2
PBJUXNIDOLNGHT-UHFFFAOYSA-N n-[6-[6-chloro-5-(methanesulfonamido)pyridin-3-yl]-1,3-benzothiazol-2-yl]acetamide Chemical compound C1=C2SC(NC(=O)C)=NC2=CC=C1C1=CN=C(Cl)C(NS(C)(=O)=O)=C1 PBJUXNIDOLNGHT-UHFFFAOYSA-N 0.000 claims description 2
DRUVAPFLWLRUDS-UHFFFAOYSA-N n-[6-[7-(methanesulfonamido)-1h-indol-5-yl]-1,3-benzothiazol-2-yl]acetamide Chemical compound CS(=O)(=O)NC1=C2NC=CC2=CC(C2=CC=C3N=C(SC3=C2)NC(=O)C)=C1 DRUVAPFLWLRUDS-UHFFFAOYSA-N 0.000 claims description 2
238000007911 parenteral administration Methods 0.000 claims description 2
ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 claims description 2
229940116357 potassium thiocyanate Drugs 0.000 claims description 2
125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims description 2
125000000168 pyrrolyl group Chemical group 0.000 claims description 2
201000000306 sarcoidosis Diseases 0.000 claims description 2
239000007787 solid Substances 0.000 claims description 2
206010041823 squamous cell carcinoma Diseases 0.000 claims description 2
239000007858 starting material Substances 0.000 claims description 2
238000007920 subcutaneous administration Methods 0.000 claims description 2
125000001113 thiadiazolyl group Chemical group 0.000 claims description 2
125000001544 thienyl group Chemical group 0.000 claims description 2
230000000699 topical effect Effects 0.000 claims description 2
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
201000005112 urinary bladder cancer Diseases 0.000 claims description 2
230000009385 viral infection Effects 0.000 claims description 2
102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 claims 28
ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims 2
XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 claims 1
208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
208000017897 Carcinoma of esophagus Diseases 0.000 claims 1
102000004353 Class I Phosphatidylinositol 3-Kinases Human genes 0.000 claims 1
108010017000 Class I Phosphatidylinositol 3-Kinases Proteins 0.000 claims 1
208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims 1
208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
230000008878 coupling Effects 0.000 claims 1
238000010168 coupling process Methods 0.000 claims 1
238000005859 coupling reaction Methods 0.000 claims 1
125000001041 indolyl group Chemical group 0.000 claims 1
208000027866 inflammatory disease Diseases 0.000 claims 1
239000000543 intermediate Substances 0.000 abstract description 9
102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 abstract 1
102000038030 PI3Ks Human genes 0.000 description 83
150000003254 radicals Chemical class 0.000 description 60
150000001602 bicycloalkyls Chemical group 0.000 description 31
125000004432 carbon atom Chemical group C* 0.000 description 31
125000002993 cycloalkylene group Chemical group 0.000 description 29
210000004027 cell Anatomy 0.000 description 25
125000004429 atom Chemical group 0.000 description 17
239000000047 product Substances 0.000 description 17
125000002947 alkylene group Chemical group 0.000 description 15
125000001118 alkylidene group Chemical group 0.000 description 15
125000003367 polycyclic group Chemical group 0.000 description 15
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 14
108091000080 Phosphotransferase Proteins 0.000 description 14
125000004435 hydrogen atom Chemical group [H]* 0.000 description 14
102000020233 phosphotransferase Human genes 0.000 description 14
239000003112 inhibitor Substances 0.000 description 13
230000011664 signaling Effects 0.000 description 13
125000004450 alkenylene group Chemical group 0.000 description 12
125000004419 alkynylene group Chemical group 0.000 description 12
125000002950 monocyclic group Chemical group 0.000 description 12
102000001253 Protein Kinase Human genes 0.000 description 11
125000002619 bicyclic group Chemical group 0.000 description 11
108060006633 protein kinase Proteins 0.000 description 11
230000001105 regulatory effect Effects 0.000 description 11
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 11
229940002612 prodrug Drugs 0.000 description 10
239000000651 prodrug Substances 0.000 description 10
108090000623 proteins and genes Proteins 0.000 description 10
102000004169 proteins and genes Human genes 0.000 description 9
239000002253 acid Substances 0.000 description 8
230000001404 mediated effect Effects 0.000 description 8
235000018102 proteins Nutrition 0.000 description 8
241001465754 Metazoa Species 0.000 description 7
230000004913 activation Effects 0.000 description 7
150000002148 esters Chemical class 0.000 description 7
102000004190 Enzymes Human genes 0.000 description 6
108090000790 Enzymes Proteins 0.000 description 6
102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 description 6
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 6
229940088598 enzyme Drugs 0.000 description 6
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 6
229960002930 sirolimus Drugs 0.000 description 6
125000003003 spiro group Chemical group 0.000 description 6
SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 5
108010011536 PTEN Phosphohydrolase Proteins 0.000 description 5
102000014160 PTEN Phosphohydrolase Human genes 0.000 description 5
101710093328 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 description 5
102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 description 5
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 5
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 5
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 5
150000001408 amides Chemical class 0.000 description 5
150000001721 carbon Chemical group 0.000 description 5
125000000623 heterocyclic group Chemical group 0.000 description 5
150000002632 lipids Chemical class 0.000 description 5
229940124302 mTOR inhibitor Drugs 0.000 description 5
239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 5
230000035772 mutation Effects 0.000 description 5
125000004433 nitrogen atom Chemical group N* 0.000 description 5
239000001301 oxygen Substances 0.000 description 5
230000037361 pathway Effects 0.000 description 5
125000006239 protecting group Chemical group 0.000 description 5
208000005623 Carcinogenesis Diseases 0.000 description 4
102100030013 Endoribonuclease Human genes 0.000 description 4
101710199605 Endoribonuclease Proteins 0.000 description 4
YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
108010035196 Mechanistic Target of Rapamycin Complex 1 Proteins 0.000 description 4
102000008135 Mechanistic Target of Rapamycin Complex 1 Human genes 0.000 description 4
UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 4
SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
101710113029 Serine/threonine-protein kinase Proteins 0.000 description 4
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
125000001931 aliphatic group Chemical group 0.000 description 4
MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
230000036952 cancer formation Effects 0.000 description 4
239000011203 carbon fibre reinforced carbon Substances 0.000 description 4
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
231100000504 carcinogenesis Toxicity 0.000 description 4
230000010261 cell growth Effects 0.000 description 4
125000006588 heterocycloalkylene group Chemical group 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
230000035755 proliferation Effects 0.000 description 4
239000012453 solvate Substances 0.000 description 4
239000011593 sulfur Substances 0.000 description 4
125000004434 sulfur atom Chemical group 0.000 description 4
208000011580 syndromic disease Diseases 0.000 description 4
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 3
208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 3
230000007730 Akt signaling Effects 0.000 description 3
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
102000001301 EGF receptor Human genes 0.000 description 3
108060006698 EGF receptor Proteins 0.000 description 3
HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 3
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 3
108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 3
208000002927 Hamartoma Diseases 0.000 description 3
241000282412 Homo Species 0.000 description 3
108010034057 Mechanistic Target of Rapamycin Complex 2 Proteins 0.000 description 3
102000009308 Mechanistic Target of Rapamycin Complex 2 Human genes 0.000 description 3
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
108700020796 Oncogene Proteins 0.000 description 3
229910019142 PO4 Inorganic materials 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
239000000556 agonist Substances 0.000 description 3
150000001299 aldehydes Chemical class 0.000 description 3
XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 3
230000003197 catalytic effect Effects 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
229940079593 drug Drugs 0.000 description 3
229940125436 dual inhibitor Drugs 0.000 description 3
210000002889 endothelial cell Anatomy 0.000 description 3
210000003238 esophagus Anatomy 0.000 description 3
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
229960005167 everolimus Drugs 0.000 description 3
230000014509 gene expression Effects 0.000 description 3
239000003102 growth factor Substances 0.000 description 3
230000007062 hydrolysis Effects 0.000 description 3
238000006460 hydrolysis reaction Methods 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
239000003018 immunosuppressive agent Substances 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 3
150000002576 ketones Chemical class 0.000 description 3
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 3
239000010452 phosphate Substances 0.000 description 3
230000026731 phosphorylation Effects 0.000 description 3
238000006366 phosphorylation reaction Methods 0.000 description 3
230000002265 prevention Effects 0.000 description 3
102000027426 receptor tyrosine kinases Human genes 0.000 description 3
108091008598 receptor tyrosine kinases Proteins 0.000 description 3
239000002904 solvent Substances 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
PXXNTAGJWPJAGM-UHFFFAOYSA-N vertaline Natural products C1C2C=3C=C(OC)C(OC)=CC=3OC(C=C3)=CC=C3CCC(=O)OC1CC1N2CCCC1 PXXNTAGJWPJAGM-UHFFFAOYSA-N 0.000 description 3
IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 2
FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 2
WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 2
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 2
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 2
102000007469 Actins Human genes 0.000 description 2
108010085238 Actins Proteins 0.000 description 2
241000271566 Aves Species 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
208000003170 Bronchiolo-Alveolar Adenocarcinoma Diseases 0.000 description 2
206010058354 Bronchioloalveolar carcinoma Diseases 0.000 description 2
241000282472 Canis lupus familiaris Species 0.000 description 2
241000283707 Capra Species 0.000 description 2
206010007572 Cardiac hypertrophy Diseases 0.000 description 2
208000006029 Cardiomegaly Diseases 0.000 description 2
241000282994 Cervidae Species 0.000 description 2
101150065749 Churc1 gene Proteins 0.000 description 2
201000002847 Cowden syndrome Diseases 0.000 description 2
RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
102000005768 DNA-Activated Protein Kinase Human genes 0.000 description 2
108010006124 DNA-Activated Protein Kinase Proteins 0.000 description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
241000283086 Equidae Species 0.000 description 2
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
239000005977 Ethylene Substances 0.000 description 2
241000282326 Felis catus Species 0.000 description 2
102000013446 GTP Phosphohydrolases Human genes 0.000 description 2
108091006109 GTPases Proteins 0.000 description 2
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
102000016285 Guanine Nucleotide Exchange Factors Human genes 0.000 description 2
108010067218 Guanine Nucleotide Exchange Factors Proteins 0.000 description 2
102100031561 Hamartin Human genes 0.000 description 2
101000795643 Homo sapiens Hamartin Proteins 0.000 description 2
101000605630 Homo sapiens Phosphatidylinositol 3-kinase catalytic subunit type 3 Proteins 0.000 description 2
101001120056 Homo sapiens Phosphatidylinositol 3-kinase regulatory subunit alpha Proteins 0.000 description 2
101000623857 Homo sapiens Serine/threonine-protein kinase mTOR Proteins 0.000 description 2
101000795659 Homo sapiens Tuberin Proteins 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
102100022875 Hypoxia-inducible factor 1-alpha Human genes 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
208000008770 Multiple Hamartoma Syndrome Diseases 0.000 description 2
108020005497 Nuclear hormone receptor Proteins 0.000 description 2
102000007399 Nuclear hormone receptor Human genes 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
241001494479 Pecora Species 0.000 description 2
PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 2
102100038329 Phosphatidylinositol 3-kinase catalytic subunit type 3 Human genes 0.000 description 2
102100026169 Phosphatidylinositol 3-kinase regulatory subunit alpha Human genes 0.000 description 2
102100036061 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform Human genes 0.000 description 2
102100036056 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform Human genes 0.000 description 2
102100036052 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Human genes 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
102100038239 Protein Churchill Human genes 0.000 description 2
KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
102100024908 Ribosomal protein S6 kinase beta-1 Human genes 0.000 description 2
101710108924 Ribosomal protein S6 kinase beta-1 Proteins 0.000 description 2
102000014400 SH2 domains Human genes 0.000 description 2
108050003452 SH2 domains Proteins 0.000 description 2
206010039491 Sarcoma Diseases 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
241000282887 Suidae Species 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 2
YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
102100031638 Tuberin Human genes 0.000 description 2
208000026911 Tuberous sclerosis complex Diseases 0.000 description 2
108010040002 Tumor Suppressor Proteins Proteins 0.000 description 2
102000001742 Tumor Suppressor Proteins Human genes 0.000 description 2
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
238000011319 anticancer therapy Methods 0.000 description 2
230000008901 benefit Effects 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
230000009087 cell motility Effects 0.000 description 2
230000004663 cell proliferation Effects 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
239000000470 constituent Substances 0.000 description 2
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
210000004292 cytoskeleton Anatomy 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
230000009977 dual effect Effects 0.000 description 2
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
239000003925 fat Substances 0.000 description 2
235000019197 fats Nutrition 0.000 description 2
238000002376 fluorescence recovery after photobleaching Methods 0.000 description 2
150000002440 hydroxy compounds Chemical class 0.000 description 2
229940125721 immunosuppressive agent Drugs 0.000 description 2
230000001965 increasing effect Effects 0.000 description 2
PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
150000007529 inorganic bases Chemical class 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
230000003993 interaction Effects 0.000 description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
239000003446 ligand Substances 0.000 description 2
208000016992 lung adenocarcinoma in situ Diseases 0.000 description 2
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
230000036210 malignancy Effects 0.000 description 2
208000024191 minimally invasive lung adenocarcinoma Diseases 0.000 description 2
TXXHDPDFNKHHGW-UHFFFAOYSA-N muconic acid Chemical group OC(=O)C=CC=CC(O)=O TXXHDPDFNKHHGW-UHFFFAOYSA-N 0.000 description 2
FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
125000001624 naphthyl group Chemical group 0.000 description 2
235000015097 nutrients Nutrition 0.000 description 2
150000007530 organic bases Chemical class 0.000 description 2
230000002018 overexpression Effects 0.000 description 2
125000004430 oxygen atom Chemical group O* 0.000 description 2
239000012660 pharmacological inhibitor Substances 0.000 description 2
YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
150000003906 phosphoinositides Chemical class 0.000 description 2
125000004550 quinolin-6-yl group Chemical group N1=CC=CC2=CC(=CC=C12)* 0.000 description 2
230000004044 response Effects 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical group OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
230000019491 signal transduction Effects 0.000 description 2
150000003384 small molecules Chemical class 0.000 description 2
210000002536 stromal cell Anatomy 0.000 description 2
239000000758 substrate Substances 0.000 description 2
230000001629 suppression Effects 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
229960000235 temsirolimus Drugs 0.000 description 2
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
238000012360 testing method Methods 0.000 description 2
125000004001 thioalkyl group Chemical group 0.000 description 2
238000002054 transplantation Methods 0.000 description 2
208000009999 tuberous sclerosis Diseases 0.000 description 2
239000000225 tumor suppressor protein Substances 0.000 description 2
DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 1
QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
125000003837 (C1-C20) alkyl group Chemical group 0.000 description 1
125000003161 (C1-C6) alkylene group Chemical group 0.000 description 1
MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
MBIZXFATKUQOOA-UHFFFAOYSA-N 1,3,4-thiadiazole Chemical compound C1=NN=CS1 MBIZXFATKUQOOA-UHFFFAOYSA-N 0.000 description 1
JIHQDMXYYFUGFV-UHFFFAOYSA-N 1,3,5-triazine Chemical compound C1=NC=NC=N1 JIHQDMXYYFUGFV-UHFFFAOYSA-N 0.000 description 1
IGERFAHWSHDDHX-UHFFFAOYSA-N 1,3-dioxanyl Chemical group [CH]1OCCCO1 IGERFAHWSHDDHX-UHFFFAOYSA-N 0.000 description 1
FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
AMMPLVWPWSYRDR-UHFFFAOYSA-N 1-methylbicyclo[2.2.2]oct-2-ene-4-carboxylic acid Chemical compound C1CC2(C(O)=O)CCC1(C)C=C2 AMMPLVWPWSYRDR-UHFFFAOYSA-N 0.000 description 1
125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 description 1
125000006017 1-propenyl group Chemical group 0.000 description 1
QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 1
HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 1
YGTUPRIZNBMOFV-UHFFFAOYSA-N 2-(4-hydroxybenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)C1=CC=C(O)C=C1 YGTUPRIZNBMOFV-UHFFFAOYSA-N 0.000 description 1
SCVJRXQHFJXZFZ-KVQBGUIXSA-N 2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione Chemical compound C1=2NC(N)=NC(=S)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)O1 SCVJRXQHFJXZFZ-KVQBGUIXSA-N 0.000 description 1
125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical group C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1
125000006029 2-methyl-2-butenyl group Chemical group 0.000 description 1
125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
RJWBTWIBUIGANW-UHFFFAOYSA-N 4-chlorobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Cl)C=C1 RJWBTWIBUIGANW-UHFFFAOYSA-N 0.000 description 1
AWQSAIIDOMEEOD-UHFFFAOYSA-N 5,5-Dimethyl-4-(3-oxobutyl)dihydro-2(3H)-furanone Chemical compound CC(=O)CCC1CC(=O)OC1(C)C AWQSAIIDOMEEOD-UHFFFAOYSA-N 0.000 description 1
125000004539 5-benzimidazolyl group Chemical group N1=CNC2=C1C=CC(=C2)* 0.000 description 1
YPWFNLSXQIGJCK-UHFFFAOYSA-N 7-oxabicyclo[2.2.1]heptane Chemical compound C1CC2CCC1O2 YPWFNLSXQIGJCK-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
206010003591 Ataxia Diseases 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
208000033929 Birt-Hogg-Dubé syndrome Diseases 0.000 description 1
WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
101710167800 Capsid assembly scaffolding protein Proteins 0.000 description 1
102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
206010008342 Cervix carcinoma Diseases 0.000 description 1
WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
108091007958 Class I PI3Ks Proteins 0.000 description 1
208000012609 Cowden disease Diseases 0.000 description 1
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical group C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Chemical group OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
241001125671 Eretmochelys imbricata Species 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Chemical group OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
102000009465 Growth Factor Receptors Human genes 0.000 description 1
108010009202 Growth Factor Receptors Proteins 0.000 description 1
206010053759 Growth retardation Diseases 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 1
101001046870 Homo sapiens Hypoxia-inducible factor 1-alpha Proteins 0.000 description 1
101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
108050009527 Hypoxia-inducible factor-1 alpha Proteins 0.000 description 1
101150026109 INSR gene Proteins 0.000 description 1
101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 description 1
102100023915 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
102100037852 Insulin-like growth factor I Human genes 0.000 description 1
102000001702 Intracellular Signaling Peptides and Proteins Human genes 0.000 description 1
108010068964 Intracellular Signaling Peptides and Proteins Proteins 0.000 description 1
OWIKHYCFFJSOEH-UHFFFAOYSA-N Isocyanic acid Chemical class N=C=O OWIKHYCFFJSOEH-UHFFFAOYSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical group OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
208000022010 Lhermitte-Duclos disease Diseases 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
241001024304 Mino Species 0.000 description 1
TXXHDPDFNKHHGW-CCAGOZQPSA-N Muconic acid Chemical group OC(=O)\C=C/C=C\C(O)=O TXXHDPDFNKHHGW-CCAGOZQPSA-N 0.000 description 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
238000005481 NMR spectroscopy Methods 0.000 description 1
208000009905 Neurofibromatoses Diseases 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
239000012828 PI3K inhibitor Substances 0.000 description 1
102100027913 Peptidyl-prolyl cis-trans isomerase FKBP1A Human genes 0.000 description 1
102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
102000010995 Pleckstrin homology domains Human genes 0.000 description 1
108050001185 Pleckstrin homology domains Proteins 0.000 description 1
101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
208000007531 Proteus syndrome Diseases 0.000 description 1
WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
101150020518 RHEB gene Proteins 0.000 description 1
102000046951 Ras Homolog Enriched in Brain Human genes 0.000 description 1
108700019578 Ras Homolog Enriched in Brain Proteins 0.000 description 1
102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
108091078243 Rho family Proteins 0.000 description 1
102000042463 Rho family Human genes 0.000 description 1
101710204410 Scaffold protein Proteins 0.000 description 1
102100026715 Serine/threonine-protein kinase STK11 Human genes 0.000 description 1
101710181599 Serine/threonine-protein kinase STK11 Proteins 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
241000187391 Streptomyces hygroscopicus Species 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
108010006877 Tacrolimus Binding Protein 1A Proteins 0.000 description 1
108010027179 Tacrolimus Binding Proteins Proteins 0.000 description 1
102000018679 Tacrolimus Binding Proteins Human genes 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
101710173511 Tensin homolog Proteins 0.000 description 1
FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
208000024770 Thyroid neoplasm Diseases 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
208000002495 Uterine Neoplasms Diseases 0.000 description 1
208000024248 Vascular System injury Diseases 0.000 description 1
208000012339 Vascular injury Diseases 0.000 description 1
206010047741 Vulval cancer Diseases 0.000 description 1
208000004354 Vulvar Neoplasms Diseases 0.000 description 1
RQQIRMLGKSPXSE-WIPMOJCBSA-N [1-acetyloxy-2-[[(2s,3r,5s,6s)-2,6-dihydroxy-3,4,5-triphosphonooxycyclohexyl]oxy-hydroxyphosphoryl]oxyethyl] acetate Chemical compound CC(=O)OC(OC(C)=O)COP(O)(=O)OC1[C@H](O)[C@H](OP(O)(O)=O)C(OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H]1O RQQIRMLGKSPXSE-WIPMOJCBSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
125000004423 acyloxy group Chemical group 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
229940024606 amino acid Drugs 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
125000004103 aminoalkyl group Chemical group 0.000 description 1
239000002870 angiogenesis inducing agent Substances 0.000 description 1
230000002491 angiogenic effect Effects 0.000 description 1
125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
239000003429 antifungal agent Substances 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
125000003710 aryl alkyl group Chemical group 0.000 description 1
150000004646 arylidenes Chemical group 0.000 description 1
230000004900 autophagic degradation Effects 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
239000002585 base Substances 0.000 description 1
RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
229940077388 benzenesulfonate Drugs 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
229940092714 benzenesulfonic acid Drugs 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
OGODKNYCTJYXFF-UHFFFAOYSA-N bis(4-methylbenzoyl) 2,3-dihydroxybutanedioate Chemical compound C1=CC(C)=CC=C1C(=O)OC(=O)C(O)C(O)C(=O)OC(=O)C1=CC=C(C)C=C1 OGODKNYCTJYXFF-UHFFFAOYSA-N 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 1
229940116229 borneol Drugs 0.000 description 1
125000001246 bromo group Chemical group Br* 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
239000000920 calcium hydroxide Substances 0.000 description 1
229910001861 calcium hydroxide Inorganic materials 0.000 description 1
150000001715 carbamic acids Chemical class 0.000 description 1
125000002837 carbocyclic group Chemical group 0.000 description 1
125000004452 carbocyclyl group Chemical group 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
210000004413 cardiac myocyte Anatomy 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000003915 cell function Effects 0.000 description 1
230000012292 cell migration Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000033077 cellular process Effects 0.000 description 1
230000005754 cellular signaling Effects 0.000 description 1
201000010881 cervical cancer Diseases 0.000 description 1
230000008859 change Effects 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
235000013985 cinnamic acid Nutrition 0.000 description 1
229930016911 cinnamic acid Natural products 0.000 description 1
WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
229960004106 citric acid Drugs 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
208000029742 colonic neoplasm Diseases 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
HCAJEUSONLESMK-UHFFFAOYSA-M cyclohexylsulfamate Chemical compound [O-]S(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-M 0.000 description 1
125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
125000000058 cyclopentadienyl group Chemical group C1(=CC=CC1)* 0.000 description 1
125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
125000004856 decahydroquinolinyl group Chemical group N1(CCCC2CCCCC12)* 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
229910052805 deuterium Inorganic materials 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
125000004663 dialkyl amino group Chemical group 0.000 description 1
230000003205 diastolic effect Effects 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 1
MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical group CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
229940043264 dodecyl sulfate Drugs 0.000 description 1
238000007876 drug discovery Methods 0.000 description 1
230000008482 dysregulation Effects 0.000 description 1
239000012636 effector Substances 0.000 description 1
ZSWFCLXCOIISFI-UHFFFAOYSA-N endo-cyclopentadiene Chemical group C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 1
230000003511 endothelial effect Effects 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000002532 enzyme inhibitor Substances 0.000 description 1
AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
229960001433 erlotinib Drugs 0.000 description 1
AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 description 1
125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
235000011087 fumaric acid Nutrition 0.000 description 1
230000004927 fusion Effects 0.000 description 1
229940114119 gentisate Drugs 0.000 description 1
239000000174 gluconic acid Chemical group 0.000 description 1
235000012208 gluconic acid Nutrition 0.000 description 1
229960001031 glucose Drugs 0.000 description 1
239000008103 glucose Substances 0.000 description 1
239000004220 glutamic acid Chemical group 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
229940093915 gynecological organic acid Drugs 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
150000002390 heteroarenes Chemical class 0.000 description 1
125000004446 heteroarylalkyl group Chemical group 0.000 description 1
125000005553 heteroaryloxy group Chemical group 0.000 description 1
239000000833 heterodimer Substances 0.000 description 1
125000006038 hexenyl group Chemical group 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
230000036571 hydration Effects 0.000 description 1
238000006703 hydration reaction Methods 0.000 description 1
230000007954 hypoxia Effects 0.000 description 1
MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
125000003114 inden-1-yl group Chemical group [H]C1=C([H])C([H])(*)C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
125000004531 indol-5-yl group Chemical group [H]N1C([H])=C([H])C2=C([H])C(*)=C([H])C([H])=C12 0.000 description 1
125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
102000006495 integrins Human genes 0.000 description 1
108010044426 integrins Proteins 0.000 description 1
230000010189 intracellular transport Effects 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
125000002346 iodo group Chemical group I* 0.000 description 1
230000005865 ionizing radiation Effects 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
125000000654 isopropylidene group Chemical group C(C)(C)=* 0.000 description 1
ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
230000000155 isotopic effect Effects 0.000 description 1
CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
208000037841 lung tumor Diseases 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
208000026037 malignant tumor of neck Diseases 0.000 description 1
229960002510 mandelic acid Drugs 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
238000013508 migration Methods 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
238000003032 molecular docking Methods 0.000 description 1
210000000214 mouth Anatomy 0.000 description 1
JHGFPKWDFAFFFO-UHFFFAOYSA-N n-(5-bromo-[1,3]thiazolo[5,4-b]pyridin-2-yl)acetamide Chemical compound C1=C(Br)N=C2SC(NC(=O)C)=NC2=C1 JHGFPKWDFAFFFO-UHFFFAOYSA-N 0.000 description 1
VGPBPWRBXBKGRE-UHFFFAOYSA-N n-(oxomethylidene)hydroxylamine Chemical compound ON=C=O VGPBPWRBXBKGRE-UHFFFAOYSA-N 0.000 description 1
SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
JTSLALYXYSRPGW-UHFFFAOYSA-N n-[5-(4-cyanophenyl)-1h-pyrrolo[2,3-b]pyridin-3-yl]pyridine-3-carboxamide Chemical compound C=1C=CN=CC=1C(=O)NC(C1=C2)=CNC1=NC=C2C1=CC=C(C#N)C=C1 JTSLALYXYSRPGW-UHFFFAOYSA-N 0.000 description 1
KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
201000004931 neurofibromatosis Diseases 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
150000002829 nitrogen Chemical group 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
SJYNFBVQFBRSIB-UHFFFAOYSA-N norbornadiene Chemical compound C1=CC2C=CC1C2 SJYNFBVQFBRSIB-UHFFFAOYSA-N 0.000 description 1
UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical compound C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 1
JFNLZVQOOSMTJK-KNVOCYPGSA-N norbornene Chemical compound C1[C@@H]2CC[C@H]1C=C2 JFNLZVQOOSMTJK-KNVOCYPGSA-N 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
230000006548 oncogenic transformation Effects 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Chemical group OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 1
125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 1
LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
125000005936 piperidyl group Chemical group 0.000 description 1
IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
OSFBJERFMQCEQY-UHFFFAOYSA-N propylidene Chemical group [CH]CC OSFBJERFMQCEQY-UHFFFAOYSA-N 0.000 description 1
108010043671 prostatic acid phosphatase Proteins 0.000 description 1
230000004224 protection Effects 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
DNXIASIHZYFFRO-UHFFFAOYSA-N pyrazoline Chemical compound C1CN=NC1 DNXIASIHZYFFRO-UHFFFAOYSA-N 0.000 description 1
125000002098 pyridazinyl group Chemical group 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
125000006513 pyridinyl methyl group Chemical group 0.000 description 1
125000000719 pyrrolidinyl group Chemical group 0.000 description 1
ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 description 1
125000001422 pyrrolinyl group Chemical group 0.000 description 1
229940107700 pyruvic acid Drugs 0.000 description 1
125000004260 quinazolin-2-yl group Chemical group [H]C1=NC(*)=NC2=C1C([H])=C([H])C([H])=C2[H] 0.000 description 1
JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
ZHNFLHYOFXQIOW-LPYZJUEESA-N quinine sulfate dihydrate Chemical compound [H+].[H+].O.O.[O-]S([O-])(=O)=O.C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21.C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 ZHNFLHYOFXQIOW-LPYZJUEESA-N 0.000 description 1
125000004159 quinolin-2-yl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C([H])C(*)=NC2=C1[H] 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
108700042226 ras Genes Proteins 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000008521 reorganization Effects 0.000 description 1
208000037803 restenosis Diseases 0.000 description 1
229960001860 salicylate Drugs 0.000 description 1
YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
238000000926 separation method Methods 0.000 description 1
230000007781 signaling event Effects 0.000 description 1
238000009097 single-agent therapy Methods 0.000 description 1
102000030938 small GTPase Human genes 0.000 description 1
108060007624 small GTPase Proteins 0.000 description 1
208000000649 small cell carcinoma Diseases 0.000 description 1
101150015916 smg1 gene Proteins 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
239000008117 stearic acid Chemical group 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
239000000126 substance Substances 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
125000001010 sulfinic acid amide group Chemical group 0.000 description 1
150000003455 sulfinic acids Chemical class 0.000 description 1
229940124530 sulfonamide Drugs 0.000 description 1
150000003456 sulfonamides Chemical class 0.000 description 1
150000003871 sulfonates Chemical class 0.000 description 1
150000003457 sulfones Chemical class 0.000 description 1
150000003460 sulfonic acids Chemical class 0.000 description 1
150000003462 sulfoxides Chemical class 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
239000003826 tablet Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 1
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
125000003831 tetrazolyl group Chemical group 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
125000005297 thienyloxy group Chemical group S1C(=CC=C1)O* 0.000 description 1
150000007970 thio esters Chemical class 0.000 description 1
150000003556 thioamides Chemical class 0.000 description 1
125000005323 thioketone group Chemical group 0.000 description 1
125000004055 thiomethyl group Chemical group [H]SC([H])([H])* 0.000 description 1
229930192474 thiophene Natural products 0.000 description 1
201000002510 thyroid cancer Diseases 0.000 description 1
125000005424 tosyloxy group Chemical group S(=O)(=O)(C1=CC=C(C)C=C1)O* 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
230000014616 translation Effects 0.000 description 1
230000032258 transport Effects 0.000 description 1
229910052722 tritium Inorganic materials 0.000 description 1
229960004418 trolamine Drugs 0.000 description 1
230000005747 tumor angiogenesis Effects 0.000 description 1
230000005740 tumor formation Effects 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
206010046766 uterine cancer Diseases 0.000 description 1
208000019553 vascular disease Diseases 0.000 description 1
210000005166 vasculature Anatomy 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
201000005102 vulva cancer Diseases 0.000 description 1